Fig. 4: Prognostic impact of MAC vs RIC on outcomes in each age sub-group.

Cumulative incidence of relapse (a) and treatment related mortality (b) in each age group are shown. Outcomes in the 51–55-year age group are shown for c OS, d acute GVHD, and cumulative incidence of e relapse and f TRM. Outcomes in the 55-60-year age group are shown for g OS, h acute GVHD, and cumulative incidence of i relapse and j TRM.